PD-1 and PD-L1 immune checkpoint inhibitors, effective in the treatment of lung cancer are now approved and/or used for all settings viz neoadjuvant, adjuvant and metastatic either alone or in combination with chemotherapy. Here, CD274 is linked to lung cancer.